The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Pre-clinical activity of UCARTCS1 in multiple myeloma
Charlotte Korst, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, discusses a study investigating the pre-clinical activity of UCARTCS1 in multiple myeloma (MM). Dr Korst highlights that these CAR-T cells were tested on myeloma cell lines and bone marrow samples from patients, as well as a mouse model. Findings from this study indicate that UCARTCS1 is highly effective in patients with both newly diagnosed and heavily pre-treated disease, and may provide an alternative treatment strategy for patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
